Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors - PubMed (original) (raw)
Case Reports
doi: 10.1210/jc.2008-1972. Epub 2008 Nov 18.
Maria E Cabanillas, Libero Santarpia, Eric Jonasch, Karen L Kyle, Elizabeth A Lano, Surena F Matin, Rodolfo F Nunez, Nancy D Perrier, Alexandria Phan, Thereasa A Rich, Beejal Shah, Michelle D Williams, Steven G Waguespack
Affiliations
- PMID: 19017755
- DOI: 10.1210/jc.2008-1972
Case Reports
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors
Camilo Jimenez et al. J Clin Endocrinol Metab. 2009 Feb.
Abstract
Context: von Hippel-Lindau disease is characterized by highly vascularized tumors of multiple organs.
Evidence acquisition: We present a patient with von Hippel-Lindau disease with multiple renal and pancreatic tumors and a malignant pheochromocytoma infiltrative of the sacrum and associated with lymph nodule metastases. The pheochromocytoma expressed high protein level of vascular endothelial growth factor and platelet-derived growth factor-beta receptor. The patient presented with a poor performance status, severe pelvic pain, weight loss, and manifestations of catecholamine excess.
Evidence synthesis: Treatment against malignant pheochromocytoma with surgery, chemotherapy, or participation in clinical trials was not feasible because of the patient's poor performance status, the presence of multiple tumors, and the extension of the pheochromocytoma into the bones. Patient was treated with sunitinib, a potent tyrosine kinase inhibitor of vascular endothelial growth factor, platelet-derived growth factor, RET, c-KIT, and FLT-3 receptors. Six months of treatment with sunitinib was associated with normalization of the patient's performance status and blood pressure, absence of symptoms of catecholamine excess, weight gain, disappearance of pain, shrinkage of each of the tumors (50% in the largest renal tumor, 38% in the largest islet cell tumor, 21% in the pelvic malignant pheochromocytoma), and reduction of plasma normetanephrines and chromogranin A.
Conclusion: This study provides evidence that targeting tyrosine kinase receptors such as the vascular endothelial growth factor pathway and the platelet-derived growth factor-beta receptor may have value in the treatment of VHL-related tumors including pheochromocytoma.
Similar articles
- Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma.
Walther MM, Reiter R, Keiser HR, Choyke PL, Venzon D, Hurley K, Gnarra JR, Reynolds JC, Glenn GM, Zbar B, Linehan WM. Walther MM, et al. J Urol. 1999 Sep;162(3 Pt 1):659-64. doi: 10.1097/00005392-199909010-00004. J Urol. 1999. PMID: 10458336 - Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease.
Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G. Neumann HP, et al. N Engl J Med. 1993 Nov 18;329(21):1531-8. doi: 10.1056/NEJM199311183292103. N Engl J Med. 1993. PMID: 8105382 - Intrathoracic and multiple abdominal pheochromocytomas in von Hippel-Lindau disease.
Hoffman RW, Gardner DW, Mitchell FL. Hoffman RW, et al. Arch Intern Med. 1982 Oct;142(10):1962-4. Arch Intern Med. 1982. PMID: 7125783 - Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1.
Opocher G, Conton P, Schiavi F, Macino B, Mantero F. Opocher G, et al. Fam Cancer. 2005;4(1):13-6. doi: 10.1007/s10689-004-6128-y. Fam Cancer. 2005. PMID: 15883705 Review. - Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment.
Shuin T, Yamasaki I, Tamura K, Okuda H, Furihata M, Ashida S. Shuin T, et al. Jpn J Clin Oncol. 2006 Jun;36(6):337-43. doi: 10.1093/jjco/hyl052. Jpn J Clin Oncol. 2006. PMID: 16818478 Review.
Cited by
- Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.
Nölting S, Grossman AB. Nölting S, et al. Endocr Pathol. 2012 Mar;23(1):21-33. doi: 10.1007/s12022-012-9199-6. Endocr Pathol. 2012. PMID: 22391976 Review. - Diagnostic features and therapeutic strategies for malignant paraganglioma in a patient: A case report.
Gan L, Shen XD, Ren Y, Cui HX, Zhuang ZX. Gan L, et al. World J Clin Cases. 2022 Sep 26;10(27):9834-9844. doi: 10.12998/wjcc.v10.i27.9834. World J Clin Cases. 2022. PMID: 36186170 Free PMC article. - Treatment of malignant pheochromocytoma.
Adjallé R, Plouin PF, Pacak K, Lehnert H. Adjallé R, et al. Horm Metab Res. 2009 Sep;41(9):687-96. doi: 10.1055/s-0029-1231025. Epub 2009 Aug 11. Horm Metab Res. 2009. PMID: 19672813 Free PMC article. Review. - A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ, Krzyzanowska M, Reuther D, Chin S, Wang L, Brooks K, Hansen AR, Asa SL, Knox JJ. O'Kane GM, et al. Br J Cancer. 2019 Jun;120(12):1113-1119. doi: 10.1038/s41416-019-0474-x. Epub 2019 May 20. Br J Cancer. 2019. PMID: 31105270 Free PMC article. Clinical Trial. - VHL syndrome without clear family history: A rare case report and literature review of Chinese patients.
Li Y, Xin X, Song W, Zhang X, Chen S, Wang Q, Li A, Li Y. Li Y, et al. Front Neurol. 2022 Oct 17;13:951054. doi: 10.3389/fneur.2022.951054. eCollection 2022. Front Neurol. 2022. PMID: 36324386 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous